|
O'Reilly, S; Hartman, N R; Bowling, K M et al. (2001) Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine. Cancer Chemother Pharmacol 48:223-8
|
|
Carducci, M A; Gilbert, J; Bowling, M K et al. (2001) A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7:3047-55
|
|
O'Reilly, S; Grochow, L B; Donehower, R C et al. (1997) Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors. J Clin Oncol 15:1974-84
|
|
Rowinsky, E K; Kaufmann, S H; Baker, S D et al. (1996) Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14:3074-84
|
|
O'Reilly, S; Rowinsky, E K; Slichenmyer, W et al. (1996) Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 14:3062-73
|
|
Hartman, N R; O'Reilly, S; Rowinsky, E K et al. (1996) Murine and human in vivo penclomedine metabolism. Clin Cancer Res 2:953-62
|
|
Chaudhry, V; Rowinsky, E K; Sartorius, S E et al. (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35:304-11
|
